Federal Trade Commission sues leading transgender health group
Federal Trade Commission sues leading transgender health group
Federal Trade Commission sues leading transgender – On Wednesday, the Federal Trade Commission (FTC) joined by Alaska, Iowa, Nebraska, and Texas launched a lawsuit against the World Professional Association for Transgender Health (WPATH). This marks another step in efforts by the Trump administration and other entities to restrict access to transgender care for minors. The legal action centers on allegations that WPATH disseminated misleading information about pediatric medical transition services, enabling its members to gain financially from these claims.
According to the complaint, WPATH’s guidelines are accused of promoting care that prioritizes profit over the health and safety of children. The FTC claims that the organization failed to adequately inform parents and patients about potential side effects of treatments such as hormone therapy. These omissions, the suit argues, allowed medical professionals to propagate “false, misleading or unsubstantiated statements” regarding the effectiveness and safety of such interventions.
“Parents have a right to make informed decisions about their children’s health,” said FTC Chairman Andrew Ferguson on X. “The FTC will not allow parents and children to be deceived by medical organizations and providers who are prioritizing profit over children’s health and safety.”
The lawsuit seeks to prevent WPATH from continuing its practices and requests a federal judge to block future violations of the FTC Act. It also aims to secure civil penalties and financial awards for the involved states. WPATH, however, defended its approach, emphasizing that its standards are patient-centered and designed to accommodate individual needs. In a statement, the organization highlighted that its guidelines are based on “established scientific standards, expert consensus, and patient-centered values.” They stressed that care plans are developed collaboratively with families and medical experts, often involving supportive talk therapy and, in some cases, puberty blockers or hormone treatments.
Lawrence Gostin, an international public health expert at Georgetown University, called the lawsuit a “significant expansion” of the FTC’s role in healthcare enforcement. He noted that the agency is using consumer protection laws to challenge the scientific foundations of clinical guidelines. Gostin expressed concern that the Trump administration has repeatedly framed transgender health as a cultural and political issue, potentially influencing the FTC’s approach to medical standards. “The FTC would be highly unlikely to second-guess clinical guidelines in areas that do not align with its political agenda,” he said.
The Department of Health and Human Services (HHS) has endorsed the FTC’s actions, citing an internal review that questioned the validity of WPATH’s standards. However, this report faced criticism from major medical groups and advocates for transgender youth, who argued it lacked scientific rigor. Transgender care for adolescents typically involves a tailored approach, combining psychological support with medical interventions that may or may not include puberty blockers or hormone therapy. Many young people with gender dysphoria choose to delay or forgo these treatments, according to the organization’s website.
The legal battle began after the FTC initiated an investigation into WPATH. The group contested the probe, claiming it violated its First Amendment rights by targeting its professional autonomy. In May, a federal judge temporarily halted the investigation, ruling in favor of WPATH. The decision underscored the organization’s position that its standards are not just clinical recommendations but also a form of protected speech.
Additionally, the FTC has scrutinized the American Academy of Pediatrics (AAP) and the Endocrine Society for their own guidelines on transgender care. Both groups have also filed lawsuits opposing the agency’s actions. WPATH pointed to these previous rulings as evidence of the FTC’s “relentless and targeted campaign” to undermine gender-affirming care. They argued that the agency is using the First Amendment to justify its attacks, which they claim are motivated by political bias rather than scientific evidence.
Transgender care for minors is a topic of growing debate, with advocates emphasizing its benefits and critics highlighting potential risks. The lawsuit reflects broader tensions between regulatory oversight and medical autonomy, as well as the role of healthcare providers in shaping patient outcomes. According to a five-year study, fewer than 1 in 1,000 U.S. adolescents received medication related to transgender care, such as puberty blockers or hormones. This statistic underscores the limited scope of such treatments and the importance of informed decision-making for families.
WPATH’s legal team is preparing to argue that the FTC’s actions are part of a larger effort to politicize medical standards. They claim the agency’s focus on the “one size fits all” approach of its guidelines is an overreach, ignoring the nuanced, individualized care that the organization advocates. “We expect the same result when we oppose this latest attack on WPATH and its mission to promote evidence-informed care and guidance for doctors and their patients,” the statement added.
The case highlights how the FTC is expanding its authority into medical practice, using consumer protection laws to challenge the integrity of professional organizations. Critics argue this could set a precedent for future interventions in healthcare, potentially limiting the autonomy of medical groups to set standards based on scientific consensus. Meanwhile, supporters of the lawsuit contend that transparency and accountability are essential to protect patients from misleading information that might influence their choices.
